Teva in Advanced Talks to Buy Allergan's Generic-drug Unit, Valued at About $45 Billion

If Teva clinches a deal with Allergan and drops its bid for Mylan, this would likely strengthen the hand of Mylan's management in its campaign to buy Perrigo.

Greg Roumeliotis
Send in e-mailSend in e-mail
Teva's plant in Jerusalem.Credit: Bloomberg

Comments